FIELD: medicine; pharmacology.
SUBSTANCE: use of peptide of the formula Ac-Thr-Gly-Glu-Asn-His-Arg-NH2 as an agent increasing relative content of high-differentiated cells and reducing relative content of low-differentiated cells in human invasive mammary gland carcinoma of a non-specific type is proposed, wherein the specified reduction is performed by transformation of cells with increasing their differentiation, and not by their destruction.
EFFECT: when using Ac-Thr-Gly-Glu-Asn-His-Arg-NH2, a cytotoxic effect is absent, and there is no enhancing of dystrophic degenerative changes, as well as no enhancing of apoptosis processes.
1 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICAL PRODUCT REDUCING CONTENT OF POORLY DIFFERENTIATED CELLS AND INCREASING CONTENT OF HIGHLY DIFFERENTIATED CELLS IN NON-SPECIFIC INVASIVE BREAST CARCINOMA | 2019 |
|
RU2743710C1 |
| PEPTIDE, POSSESSING ANTI-TUMOR AND ANTI-METASTATIC ACTIVITY, AND FINISHED DOSAGE FORM BASED THEREON | 2018 |
|
RU2682039C1 |
| METHOD FOR PRODUCING PEPTIDE EXENATIDE | 2011 |
|
RU2458066C1 |
| PEPTIDE STIMULATING FORMATION OF SPECIFIC ANTIBODIES HAVING EFFECT ON SURVIVIN IN TUMOUR TISSUE | 2009 |
|
RU2396277C1 |
| METASTIN DERIVATIVES AND APPLICATION THEREOF | 2006 |
|
RU2430107C2 |
| COMPOSITION FOR INCREASING CONTENT OF HIGHLY DIFFERENTIATED CELLS IN BREAST ADENOCARCINOMA | 2018 |
|
RU2697199C1 |
| SYNTHESIS OF LIXISENATIDE WITH CAPPING | 2019 |
|
RU2782772C2 |
| PEPTIDE HAVING ACTIVITY OF HUMAN SLURP-1 PROTEIN AND ITS APPLICATION FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA, PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA, AND METHOD FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA USING THE SPECIFIED PEPTIDE | 2022 |
|
RU2792364C1 |
| EXENATIDE ANALOGUE | 2020 |
|
RU2823623C1 |
| METHOD FOR CLEAVAGE OF SOLID PHASE-BOUND PEPTIDES FROM THE SOLID PHASE | 2019 |
|
RU2771712C2 |
